Shopping Cart 0
Cart Subtotal
AED 0

Sumitomo Dainippon Pharma Co Ltd (4506) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd (4506)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19

Venture Financing 21

Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21

Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22

Matrizyme Pharma Raises USD9 Million in Financing 23

Tolero Pharma Raises USD 3.33 Million In Venture Financing 24

Elevation Pharma Secures USD 30 Million In Series B Financing 25

Private Equity 27

Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27

Partnerships 28

Tolero Pharma Enters into Research Agreement with AbbVie 28

Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29

Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30

Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32

Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34

FunPep Enters into Research Agreement with Sumitomo Dainippon 35

Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36

Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37

Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38

ex scientia Enters into Research Agreement with Sunovion Pharma 39

Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40

Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42

Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43

Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44

Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45

Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46

PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48

Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49

Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50

Licensing Agreements 51

Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51

Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52

Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53

Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55

Sunovion Pharma Enters into Licensing Agreement with Novartis 56

Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59

SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62

Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65

Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68

Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69

Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 73

Equity Offering 74

Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76

Cynapsus Therapeutics Completes Public Offering Of Units For USD 22.8 Million 78

Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.3 Million 79

Cynapsus Therapeutics Completes Private Placement Of Units For USD 1 Million 81

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.2 Million 82

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.1 Million 83

Debt Offering 84

Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For USD 1.1 Million 84

Asset Transactions 86

Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87

Acquisition 88

Sumitomo Dainippon Pharma Acquires Tolero Pharma 88

Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90

Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For USD 16 Million 92

Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To USD 430 Million 93

Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95

Sumitomo Dainippon Pharma Co Ltd-Key Competitors 97

Sumitomo Dainippon Pharma Co Ltd-Key Employees 98

Sumitomo Dainippon Pharma Co Ltd-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 103

Strategy And Business Planning 103

Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 103

Financial Announcements 104

Oct 30, 2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019 104

Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 107

May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 110

Corporate Communications 115

Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes 115

Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 116

Jun 15, 2018: Sumitomo Dainippon Pharma Announces Management Changes 117

May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 118

Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 119

Mar 29, 2017: Sumitomo Dainippon Pharma announces Changes in Executive Officers 120

Mar 22, 2017: Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical and Establishment of Global Head of Oncology 121

Legal and Regulatory 123

Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson's disease 123

Government and Public Interest 124

Jun 01, 2017: Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period 124

Product News 125

05/17/2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018 125

Product Approvals 126

Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 126

Feb 28, 2017: Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a SAKIGAKE Product by Japan's Ministry of Health, Labour and Welfare 127

Clinical Trials 128

Jul 31, 2018: Kyoto University to begin trials of iPS cells to treat Parkinson's 128

Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018 129

Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) 130

Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 131

May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 132

Other Significant Developments 133

May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma-Sumitomo Dainippon Pharma Co Ltd] 133

Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 134

Apr 10, 2017: Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells 135

Appendix 136

Methodology 136

About GlobalData 136

Contact Us 136

Disclaimer 136


List Of Figure

List of Figures

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19

Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21

Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22

Matrizyme Pharma Raises USD9 Million in Financing 23

Tolero Pharma Raises USD 3.33 Million In Venture Financing 24

Elevation Pharma Secures USD 30 Million In Series B Financing 25

Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27

Tolero Pharma Enters into Research Agreement with AbbVie 28

Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29

Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30

Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32

Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34

FunPep Enters into Research Agreement with Sumitomo Dainippon 35

Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36

Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37

Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38

ex scientia Enters into Research Agreement with Sunovion Pharma 39

Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40

Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42

Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43

Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44

Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45

Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46

PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48

Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49

Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50

Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51

Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52

Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53

Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55

Sunovion Pharma Enters into Licensing Agreement with Novartis 56

Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59

SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62

Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65

Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68

Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69

Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 73

Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76

Cynapsus Therapeutics Completes Public Offering Of Units For USD 22.8 Million 78

Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.3 Million 79

Cynapsus Therapeutics Completes Private Placement Of Units For USD 1 Million 81

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.2 Million 82

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.1 Million 83

Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For USD 1.1 Million 84

Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87

Sumitomo Dainippon Pharma Acquires Tolero Pharma 88

Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90

Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For USD 16 Million 92

Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To USD 430 Million 93

Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95

Sumitomo Dainippon Pharma Co Ltd, Key Competitors 97

Sumitomo Dainippon Pharma Co Ltd, Key Employees 98

Sumitomo Dainippon Pharma Co Ltd, Other Locations 100

Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Sumitomo Dainippon Pharma Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd (4506)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19

Venture Financing 21

Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21

Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22

Matrizyme Pharma Raises USD9 Million in Financing 23

Tolero Pharma Raises USD 3.33 Million In Venture Financing 24

Elevation Pharma Secures USD 30 Million In Series B Financing 25

Private Equity 27

Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27

Partnerships 28

Tolero Pharma Enters into Research Agreement with AbbVie 28

Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29

Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30

Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32

Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34

FunPep Enters into Research Agreement with Sumitomo Dainippon 35

Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36

Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37

Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38

ex scientia Enters into Research Agreement with Sunovion Pharma 39

Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40

Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42

Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43

Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44

Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45

Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46

PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48

Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49

Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50

Licensing Agreements 51

Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51

Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52

Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53

Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55

Sunovion Pharma Enters into Licensing Agreement with Novartis 56

Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59

SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62

Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65

Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68

Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69

Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 73

Equity Offering 74

Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76

Cynapsus Therapeutics Completes Public Offering Of Units For USD 22.8 Million 78

Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.3 Million 79

Cynapsus Therapeutics Completes Private Placement Of Units For USD 1 Million 81

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.2 Million 82

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.1 Million 83

Debt Offering 84

Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For USD 1.1 Million 84

Asset Transactions 86

Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87

Acquisition 88

Sumitomo Dainippon Pharma Acquires Tolero Pharma 88

Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90

Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For USD 16 Million 92

Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To USD 430 Million 93

Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95

Sumitomo Dainippon Pharma Co Ltd-Key Competitors 97

Sumitomo Dainippon Pharma Co Ltd-Key Employees 98

Sumitomo Dainippon Pharma Co Ltd-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 103

Strategy And Business Planning 103

Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 103

Financial Announcements 104

Oct 30, 2018: Sumitomo Dainippon: Consolidated financial results for the second quarter of the year ending March 31, 2019 104

Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 107

May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 110

Corporate Communications 115

Sep 03, 2018: Sumitomo Dainippon Pharma announces personnel changes 115

Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 116

Jun 15, 2018: Sumitomo Dainippon Pharma Announces Management Changes 117

May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 118

Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 119

Mar 29, 2017: Sumitomo Dainippon Pharma announces Changes in Executive Officers 120

Mar 22, 2017: Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical and Establishment of Global Head of Oncology 121

Legal and Regulatory 123

Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson's disease 123

Government and Public Interest 124

Jun 01, 2017: Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period 124

Product News 125

05/17/2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018 125

Product Approvals 126

Jul 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome 126

Feb 28, 2017: Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a SAKIGAKE Product by Japan's Ministry of Health, Labour and Welfare 127

Clinical Trials 128

Jul 31, 2018: Kyoto University to begin trials of iPS cells to treat Parkinson's 128

Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018 129

Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) 130

Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 131

May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 132

Other Significant Developments 133

May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma-Sumitomo Dainippon Pharma Co Ltd] 133

Jul 04, 2017: Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S. 134

Apr 10, 2017: Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells 135

Appendix 136

Methodology 136

About GlobalData 136

Contact Us 136

Disclaimer 136


List Of Figure

List of Figures

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Sumitomo Dainippon Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Sumitomo Dainippon Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 19

Tolero Pharma Raises USD8.2 Million in Second Tranche of Series B Financing 21

Tolero Pharma Raises USD14.2 Million in Series B Venture Financing 22

Matrizyme Pharma Raises USD9 Million in Financing 23

Tolero Pharma Raises USD 3.33 Million In Venture Financing 24

Elevation Pharma Secures USD 30 Million In Series B Financing 25

Orbimed Advisors Acquires Additional 3.17% Stake in Cynapsus Therapeutics for USD6.3 Million 27

Tolero Pharma Enters into Research Agreement with AbbVie 28

Sumitomo Dainippon Pharma Enters into Research Agreement with Medicines for Malaria Venture 29

Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 30

Kitasato Institute Enters into Research Agreement with Sumitomo Dainippon Pharma 31

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 32

Sharp Edge Labs Enters into Agreement with Sumitomo Dainippon Pharma 34

FunPep Enters into Research Agreement with Sumitomo Dainippon 35

Dainippon Sumitomo Pharma Extends Research Agreement with CiRA and Hitachi 36

Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 37

Japan Tobacco, Torii Pharmac and Sumitomo Dainippon Pharma Enter into Partnership 38

ex scientia Enters into Research Agreement with Sunovion Pharma 39

Dainippon Sumitomo Pharma Enters into Co-Marketing Agreement with Teikoku Seiyaku 40

Healios Forms Joint Venture With Dainippon Sumitomo Pharma 42

Eutropics Enters Into Co-Development Agreement With Tolero Pharma 43

Healios And Dainippon Sumitomo Pharma Enter Into Agreement For iPS Cell Technology 44

Sunovion Pharma Enters Into Agreement With Afraxis To Discover CNS Drugs 45

Dainippon Sumitomo Pharma Forms Joint Venture With Japan BCG Lab 46

PsychoGenics Extends Drug Discovery Agreement with Sunovion Pharma 47

Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 48

Dainippon Sumitomo Pharma Enters Into Research Agreement With Kobe University For Anti-Cancer Drugs 49

Prasco Labs Enters into Distribution Agreement with Sunovion Pharma for Xopenex 50

Sumitomo Dainippon Pharma Enters into Licensing Agreement with JCR Pharma 51

Angelini Enters into Licensing and Distribution Agreement with Sunovion Pharma 52

Sumitomo Dainippon Pharma and Poxel Form Strategic Partnership for Development and Commercialization of Imeglimin 53

Maruishi Pharma Enters into Licensing Agreement with Sumitomo Dainippon Pharma 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Bukwang Pharm 55

Sunovion Pharma Enters into Licensing Agreement with Novartis 56

Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 57

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Elixirgen 58

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 59

SanBio Enters into Licensing Agreement with Sumitomo Dainippon Pharma for SB623 60

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 62

Healios Enters Into Licensing Agreement With Dainippon Sumitomo Pharma For RPE Cells 63

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Standard Chem. & Pharm 64

Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 65

Edison Pharma Expands Licensing Agreement With Dainippon Sumitomo Pharma 66

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Nippon Shinyaku For SMP-986 68

Dnavec Enters into Licensing Agreement with Sumitomo Dainippon Pharma 69

Kobe University And KNC Labs Enter Into Licensing Agreement With Dainippon Sumitomo Pharma 70

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 72

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 73

Cynapsus Therapeutics Raises USD72.5 Million in Public Offering of Shares 74

Cynapsus Therapeutics Raises USD16.6 Million in Private Placement of Shares 76

Cynapsus Therapeutics Completes Public Offering Of Units For USD 22.8 Million 78

Cynapsus Therapeutics Completes Second Tranche Of Private Placement Of Units For USD 1.3 Million 79

Cynapsus Therapeutics Completes Private Placement Of Units For USD 1 Million 81

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.2 Million 82

Cynapsus Therapeutics Completes Private Placement Of Units For USD 0.1 Million 83

Cynapsus Therapeutics Completes Additional Public Offering Of Series E Debentures Due 2013 For USD 1.1 Million 84

Sunovion Pharma to Divest US Rights of Ciclesonide Products to Covis Pharma 86

Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 87

Sumitomo Dainippon Pharma Acquires Tolero Pharma 88

Sunovion Pharma Acquires Cynapsus Therapeutics for up to USD635 Million 90

Dainippon Sumitomo Pharma To Acquire 5% Stake In Retina Institute Japan For USD 16 Million 92

Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To USD 430 Million 93

Dainippon Sumitomo Pharma Completes Acquisition Of Boston Biomedical 95

Sumitomo Dainippon Pharma Co Ltd, Key Competitors 97

Sumitomo Dainippon Pharma Co Ltd, Key Employees 98

Sumitomo Dainippon Pharma Co Ltd, Other Locations 100

Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Sumitomo Dainippon Pharma Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.